With the World Trade Organization’s (WTO’s) Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) set to meet informally on Monday, September 19, to discuss extending a waiver of IP rights for COVID-19 vaccine-related technology to diagnostics and therapeutics, the U.S. Chamber of Commerce and the Chamber’s Global Innovation Policy Center (GIPC) are urging the Biden Administration to oppose such a move in favor of “real solutions.” The GIPC’s President and CEO, David Hirschmann, and the Chamber’s Executive Vice President and Head of International Affairs, Myron Brilliant, sent a letter to U.S. Secretary of Commerce Gina Raimondo on Friday expressing confusion at the administration’s seemingly contradictory stances on intellectual property rights.
Recent Posts
- Witnesses Tell Senate IP Subcommittee They Must Get NO FAKES Act Right
- Commerce Department Announces NIST and USPTO Actions on AI
- FCC Restores Net Neutrality Regime Amid Criticism
- Other Barks and Bites for Friday, April 26: World Intellectual Property Day Celebrated Around the Globe; China Tops List for AI Patents Granted; EPO Releases Cleantech Study on World IP Day
- Celebrating World IP Day: Is the Innovative Future Sustainable?